IC
Publications
- Recent trends in pirfenidone and nintedanib use for idiopathic pulmonary fibrosis in Australia
- Assessment of health-related quality of life in Australian patients with idiopathic pulmonary fibrosis: a comparison of the EQ-5D-5L and the AQoL-8D
- Mortality and survival in idiopathic pulmonary fibrosis: a systematic review and meta-analysis
- Health-related quality of life of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis
- Mortality and Survival in Idiopathic Pulmonary Fibrosis: An Updated Comprehensive Systematic Review and Meta-Analysis
- Mapping EQ5D Utilities From Forced Vital Capacity and Diffusing Capacity in Fibrotic Interstitial Lung Disease
- The influence of immortal time bias in observational studies examining associations of antifibrotic therapy with survival in idiopathic pulmonary fibrosis: A simulation study
- Epidemiology of Idiopathic Pulmonary Fibrosis in Australia
- The relative contribution of co-morbidities to health-related quality of life of people with idiopathic pulmonary fibrosis using the Assessment of Quality of Life-8-Dimension multi-attribute utility instrument
- P50 Comparison of the EQ-5D-5L and Aqol-8D in a cohort of people with idiopathic pulmonary fibrosis in Australia
- P43 The economic burden of idiopathic pulmonary fibrosis in Australia
- Evaluation of health-related quality of life in IPF: A systematic review and meta-analysis
- Thoracic Society of Australia and New Zealand Annual Scientific Meeting 2021
- The impact of idiopathic pulmonary fibrosis on health state utility values: evidence from Australia
- A comprehensive systematic review of data linkage publications on diabetes in Australia
- Mapping EQ5D utilities from forced vital capacity and diffusing capacity in fibrotic interstitial lung disease
- Health Related Quality of Life of Patients with Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis
- Decision Making in the Context of Funding Cancer Therapy
- PRS18 The IMPACT of Idiopathic Pulmonary Fibrosis on Health State Utility Values: Evidence from Australia
- Incidence, prevalence and mortality of idiopathic pulmonary fibrosis in Australia
- COMPARISON OF THE EQ-5D-5L AND AQOL-8D IN A COHORT OF PEOPLE WITH IDIOPATHIC PULMONARY FIBROSIS IN AUSTRALIA
- THE ECONOMIC BURDEN OF IDIOPATHIC PULMONARY FIBROSIS IN AUSTRALIA
- The economic burden of idiopathic pulmonary fibrosis in Australia: a cost of illness study
- The impact of idiopathic pulmonary fibrosis on health state utility values: evidence from Australia
- EE56 Minimally Invasive Surfactant Treatment Versus Standard Therapy in Preterm Infants at Birth (OPTIMIST-A TRIAL): An Analysis of Initial Hospitalisation Costs and Resource Consumption
- Long‐term exposure to low concentrations of air pollution and decline in lung function in people with idiopathic pulmonary fibrosis: Evidence from Australia
- Cardiovascular and health cost impacts of cuff blood pressure underestimation and overestimation of invasive aortic systolic blood pressure.
- Assessing health state utilities for people with myalgic encephalomyelitis/chronic fatigue syndrome in Australia using the EQ-5D-5L, AQoL-8D and EQ-5D-5L-psychosocial instruments
- Cardiovascular and health cost impacts of cuff blood pressure underestimation and overestimation of invasive aortic systolic blood pressure
- A Cost-Effectiveness Model for Frail Older Persons: Development and Application to a Physiotherapy-Based Intervention
- Decision-Making in the Context of Funding Cancer Therapy
- TRENDS IN NINTEDANIB AND PIRFENIDONE UTILIZATION FOR IDIOPATHIC PULMONARY FIBROSIS IN AUSTRALIA
- MINIMALLY INVASIVE SURFACTANT TREATMENT VERSUS STANDARD THERAPY IN PRETERM INFANTS AT BIRTH (OPTIMIST-A TRIAL): AN ANALYSIS OF INITIAL HOSPITALISATIONCOSTS AND RESOURCE CONSUMPTION
- ANNUAL TRANSITION PROBABILITIES FOR DISEASE SEVERITY CHANGES IN AN AUSTRALIAN COHORT OF PEOPLE WITH IDIOPATHIC PULMONARY FIBROSIS
- The economic burden of myalgic encephalomyelitis/chronic fatigue syndrome in Australia